Compare McKesson Corporation (MCK) vs Rockwell Automation (ROK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Rockwell Automation — how do they compare? McKesson Corporation trades at $899.06 (market cap $102.58B), while Rockwell Automation trades at $448.4 (market cap $48.33B). The key difference: McKesson Corporation is far larger — about 2.1× Rockwell Automation's market cap, and Rockwell Automation pays the higher dividend (1.27%). Which is the better fit depends on your goals.
| MCK | ROK | |
|---|---|---|
Market Cap | $102.58B | $48.33B |
Sector | Health | Industrials |
52-Week High | $995.69 | $495.08 |
52-Week Low | $659.01 | $333.75 |
Enterprise Value | $109.12B | $51.46B |
Dividend Yield | 0.43% | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson (MCK) trades at $869.58, down 0.14% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with revenue growth to $359.05B in 2025 and consistent earnings beats, including Q2 2026 EPS of $9.93 versus $9.56 expected. Valuation metrics like P/E of 23.33 and P/S of 0.26 indicate reasonable pricing relative to peers. Recent news highlights Q1 2027 results exceeding expectations and raised full-year guidance, driven by specialty drug and oncology growth.
Outlook remains positive with 80% analyst buy ratings and a $1,000 consensus price target, suggesting 15% upside. Risks include thin net margins of 1.12% and high liabilities at $76.83B, which could pressure equity during economic downturns. Investors should focus on execution of raised guidance and margin improvements from cost efficiencies.
Rockwell Automation (ROK) trades at $441.04, down 0.17% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 49.09% gross margin and 13.38% net income margin, but elevated valuation ratios like a P/E of 41.3 suggest premium pricing. Q3 2026 results exceeded expectations, driven by organic sales growth and margin expansion, prompting raised full-year guidance.
The outlook is mixed: analyst consensus leans bullish with a $480.25 price target (30% buy ratings), but technical weakness and high valuation pose near-term risks. Key catalysts include sustained automation demand and cost management, while inflation and competitive pressures remain headwinds for shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Rockwell Automation
Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →
